Skip to main content
. 2020 Sep 10;13(12):100865. doi: 10.1016/j.tranon.2020.100865

Fig. 1.

Fig. 1

Anti-PD-1 therapy overall boosted the frequency of Tregs but showed no obvious impact on M-MDSCs and G-MDSCs levels in NSCLC patients.

(A–C) The overall effect of anti-PD-1 therapy on the levels of (A) Tregs, (B) G-MDSCs, and (C) M-MDSCs. “baseline” represents before PD-1 therapy; “after anti-PD-1” represents the levels after the first anti-PD-1 therapy, N = 27. Two-tailed paired t-test was performed.

(D–F): The change of (D) Tregs, (E) G-MDSCs, and (F) M-MDSCs levels with consecutive dosage of anti-PD-1 therapy. X-axis: the times of anti-PD-1 treatment; Y-axis: the levels of Treg or G-MDSCs or M-MDSCs. The number of data of every cycle may be different because of the different follow-up duration of different patients. N = 27. Two-tailed paired t-test was performed between the baseline levels and any cycle of anti-PD-1 treatment.

ns: no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control groups. A P value less than 0.05 was considered to be statistically significant.